All In Biotech

Drug Trial Radar · NCT06721013

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Feb 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

  • PirtobrutinibDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1-Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline Up to Week 4
  2. Phase 1-Dose Limiting Toxicity (DLT) of PirtobrutinibTime frame: Baseline Up to Week 4
  3. Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Vital Signs: Blood Pressure, Pulse Rate, and Body TemperatureTime frame: Baseline Up to Week 16
  4. Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Clinical Lab Tests: Hematology, Clinical Chemistry, Urinalysis, Pregnancy, Hepatitis Serology and Cytomegalovirus (CMV)Time frame: Baseline Up to Week 16
  5. Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Electrocardiograms (ECGs): ECG QT IntervalTime frame: Baseline Up to Week 16
  6. Phase 2-Efficacy of Pirtobrutinib Versus PlaceboTime frame: Baseline Up to Week 24

Locations

43 sites in 10 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center

    Miami, Florida · Not yet recruiting

  • Bleeding and Clotting Disorders Institute

    Peoria, Illinois · Not yet recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Texas Oncology - Central South

    Austin, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology Gulf Coast

    The Woodlands, Texas · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, China · Recruiting

  • Hematology Hospital of the Chinese Academy of Medical Sciences

    Tianjin, China · Not yet recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • OUH

    Odense C, Denmark · Recruiting

  • Hôpital Henri Mondor

    Créteil, France · Recruiting

  • CHU Dijon - Hopital du Bocage

    Dijon, France · Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS

    Bologna, Italy · Recruiting

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Recruiting

  • Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI)

    Trieste, Italy · Recruiting

  • Haukeland University Hospital

    Bergen, Norway · Recruiting

  • Sykehuset Ostfold, Kalnes

    Grålum, Norway · Recruiting

  • St. Olavs Hospital Hf, Universitetssykehuset i Trondheim

    Trondheim, Norway · Recruiting

  • Pratia Onkologia Katowice

    Katowice, Poland · Recruiting

  • Pratia MCM Krakow

    Krakow, Poland · Recruiting

  • Aidport sp z o.o.

    Skorzewo, Poland · Recruiting

  • MICS Centrum Medyczne Torun

    Torun, Poland · Recruiting

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

    Wroclaw, Poland · Not yet recruiting

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Hospital Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario de Burgos

    Burgos, Spain · Recruiting

  • Hospital General Universitario Morales Meseguer

    Murcia, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Spain · Recruiting

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom · Recruiting

  • St James's University Hospital

    Leeds, United Kingdom · Recruiting

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.